News for Adicet Bio, Inc. (ACET)

Adicet Bio (ACET) has recently come under the coverage of H.C. Wainwright's analyst Robert Burns, who has given the stock a Buy rating and set a price target at

Shares of Block, Inc. XYZ rose sharply in pre-market trading ahead of the S&P 500 debut of the Jack Dorsey-founded fintech company. Block will replace Hess Cor...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

As of March 31, 2025, ACET reported holding $150.4 million in cash and cash equivalents. This figure reflects a decrease from the $176.3 million recorded at the

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (ACET) CEO, Chen Schor, to join a fireside chat at the 2025 Citizens JMP Life Sciences Conference. The event takes place on May 7, 2025

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (ACET) to present preclinical data on ADI-270 at ASGCT 2025. Presentation to highlight anti-tumor activity compared to conventional CAR

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio (ACET) appoints Michael Grissinger with over 40 years of business development expertise to its Board of Directors. Grissinger brings signific

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. ( HOWL), an innovative biopharmaceutical company pioneering the development of

**media[548365]**

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)